SOLV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, Solventum Corp (SOLV) is not a strong buy for a beginner investor with a long-term focus. The technical indicators are bearish, the options sentiment is neutral to slightly bearish, and there are no significant positive catalysts or recent news to drive the stock higher. While the company's net income and EPS have shown strong growth in the latest quarter, the revenue decline and gross margin contraction are concerning. Analyst ratings are mixed, with recent downgrades and price targets below the current pre-market price. Therefore, holding off on buying this stock is recommended.
The technical indicators for SOLV are bearish. The MACD histogram is negative and contracting, RSI is neutral at 29.942, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 66.024, with key support at 63.611 and resistance at 68.436.
The company's net income increased by 103.23% YoY in Q4 2025, and EPS grew by 100% YoY. Analysts from KeyBanc and Mizuho have upgraded the stock earlier this year, citing positive outlooks for new product launches and acquisitions.
Rothschild & Co recently initiated coverage with a Sell rating and a $60 price target, citing challenges in organic growth and lack of synergies between divisions. Technical indicators and stock trend analysis suggest a bearish outlook in the short term.
In Q4 2025, Solventum's revenue declined to $1.998 billion, down 3.71% YoY. However, net income increased significantly to $63 million (up 103.23% YoY), and EPS doubled to $0.36. Gross margin dropped to 51.4%, down 4.69% YoY.
Analyst ratings are mixed. Rothschild initiated coverage with a Sell rating and a $60 price target, while Wells Fargo maintained an Equal Weight rating with an $83 target. UBS raised its price target to $82, and KeyBanc and Mizuho have more optimistic targets of $99 and $100, respectively. However, the mixed sentiment and recent downgrades weigh on the stock's outlook.
